International epidemiology of prostate cancer: Geographical distribution and secular trends

Baade, Peter D.; Youlden, Danny R.; Krnjacki, Lauren

doi:10.1002/mnfr.200700511

Cited by 378 publications

(337 citation statements)

References 91 publications

Supporting

Mentioning

319

Contrasting

Unclassified

Order By: Relevance

“…However, this data may not be relevant to Australia, where overall testing rates tend to be lower [ 14,15 ] and where public health policies on testing vary [ 5,7,16,17 ] . In addition, key motivations for why men with a family history of prostate cancer may seek testing are not known; and preferred sources of information and support for these men in making a testing decision have not yet been described in the Australian context.…”

Section: Introductionmentioning

confidence: 99%

Patterns of prostate‐specific antigen (PSA) testing in Australian men: the influence of family history

McDowell¹,

Occhipinti²,

Gardiner³

et al. 2012

BJU International

View full text Add to dashboard Cite

INTRODUCTIONIn Australia, prostate cancer is the most prevalent cancer in men, with one in seven men diagnosed by the age of 75 years [ 1 ] . Men with a fi rst-degree family history of prostate cancer are at more than double the risk of being diagnosed than men without a family history [ 2,3 ] , although the clinical course is similar for both groups [ 4 ] . Current guidelines on the use of PSA testing for the early detection of prostate cancer recommend that men considering testing should make an informed decision about testing with their health practitioner, taking into account family history [ 5 -12 ] ; with one organisation advising that men with a family history consider testing after the age of 40 years [ 5 ] . However, there is currently little Australian data to inform how this might best occur.While it appears that having a fi rst-degree family history of prostate cancer leads to greater uptake of early detection testing [ 13 ] , rigorous data on this topic is only available from North American studies. However, this data may not be relevant to Australia, where overall testing rates tend to be lower [ 14,15 ] and where public health policies on testing vary [ 5,7,16,17 ] . In addition, key motivations for why men with a family history of prostate cancer may seek testing are not known; and preferred sources of information and support for these men in making a testing decision have not yet been described in the Australian context. With regards to the latter, in North America men rate their healthcare provider as the most important source of information about testing for prostate cancer [ 18 ] . However, discussions about prostate cancer with healthcare providers did not tend to address the ' cons ' of early detection tests.The present study targets these gaps in evidence by applying a case control methodology to examine early detection of prostate cancer testing behaviours, information needs and preferences and OBJECTIVE• To describe how a family history of prostate cancer infl uences men ' s prostate cancer testing behaviours, information support preferences, and motives for testing. SUBJECTS AND METHODS• Men with a fi rst-degree family history (239 men) and a comparison sample from the general population of Queensland, Australia (289) aged 40 -65 years, and no prior history of cancer.• Cross-sectional, retrospective survey assessing: prevalence of prostate-specifi c antigen (PSA) testing and digital rectal examination (DRE); discussion of prostate cancer risks and benefi ts with a physician; prostate cancer information needs and preferences; motivations for testing. RESULTS• Men with a family history were more likely to report: having ever had a PSA test (odds ratio [ OR ] • Most men from both groups did not recall any discussion of the ' cons ' of prostate cancer testing with a doctor.• Men with a family history reported a greater desire for information about prostate cancer prevention than did men without a family history. CONCLUSIONS• Men with a family history are more concerned about getting pros...

show abstract

Section: Introductionmentioning

confidence: 99%

Patterns of prostate‐specific antigen (PSA) testing in Australian men: the influence of family history

McDowell¹,

Occhipinti²,

Gardiner³

et al. 2012

BJU International

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is the most common cancer in males and a leading cause of cancer mortality in the U.S (Baade, Youlden et al 2009, Siegel, Ma et al 2014). The incidence of prostate cancer is quickly rising in Korea (Jung, Won et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Cytotoxic Effects of Escin on Human Castration-resistant Prostate Cancer Cells Through the Induction of Apoptosis and G2/M Cell Cycle Arrest

Piao

Kang

Lee

et al. 2014

Urology

View full text Add to dashboard Cite

“…Prostate cancer is the second leading cause of cancer related deaths in males in western countries (Siegel et al, 2012), but has a relatively low incidence in Asia, particularly in South East Asia (Baade et al, 2009). Early stage prostate cancer requires androgen for growth and thus responds well to androgen deprivation therapy (Loblaw et al, 2007), but tumors become resistant to this therapy as disease progresses (Pilat et al, 1998;So et al, 2005;Schroder, 2008;Chi et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Anticancer Activity of Acanthopanax trifoliatus (L) Merr Extracts is Associated with Inhibition of NF-κB Activity and Decreased Erk1/2 and Akt Phosphorylation

Wang

Li²,

Lu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Acanthopanax trifoliatus (L) Merr (AT) is commonly used as an herbal medicine and edible plant in some areas of China and other Asian countries. AT is thought to have anticancer effects, but potential mechanisms remain unknown. To assess the anticancer properties of AT, we exposed prostate cancer cells to AT extracts and assessed cell proliferation and signaling pathways. An ethanol extract of AT was suspended in water followed by sequential extraction with petroleum ether, ethyl acetate and n-butanol. PC-3 cells were treated with different concentrations of each extract and cell viability was determined by the MTT and trypan blue exclusion assays. The ethyl acetate extract of the ethanol extract had a stronger inhibitory effect on growth and a stronger stimulatory effect on apoptosis than any of the other extracts. Mechanistic studies demonstrated that the ethyl acetate extract suppressed the transcriptional activity of NF-kB, increased the level of caspase-3, and decreased the levels of phospho-Erk1/2 and phospho-Akt. This is the first report on the anticancer activity of AT in cultured human prostate cancer cells. The results suggest that AT can provide a plant-based medicine for the treatment or prevention of prostate cancer.

show abstract

International epidemiology of prostate cancer: Geographical distribution and secular trends

Cited by 378 publications

References 91 publications

Patterns of prostate‐specific antigen (PSA) testing in Australian men: the influence of family history

Patterns of prostate‐specific antigen (PSA) testing in Australian men: the influence of family history

Cytotoxic Effects of Escin on Human Castration-resistant Prostate Cancer Cells Through the Induction of Apoptosis and G2/M Cell Cycle Arrest

Anticancer Activity of Acanthopanax trifoliatus (L) Merr Extracts is Associated with Inhibition of NF-κB Activity and Decreased Erk1/2 and Akt Phosphorylation

Contact Info

Product

Resources

About